Cost-utility analysis of erenumab preventive treatment for chronic migraine in China.

This study looked at the cost-effectiveness of erenumab for chronic migraine in China. Erenumab is a preventive treatment given as an injection every four weeks. Researchers compared its effects to no preventive treatment at all. They used a microsimulation model to analyze data from the DRAGON trial. This trial involved Asian adults suffering from chronic migraines. The study focused on a year-long period, breaking it down into 13 cycles. They calculated costs including the price of erenumab and other medical services. The main outcome was the total cost and quality of life for patients. Results showed that erenumab could be a cost-effective option for preventing migraines. This means it might provide good value for the money spent on treatment. Overall, the research suggests that using erenumab could improve the lives of those with chronic migraines in China. Clinical relevance: This study indicates that erenumab may be a cost-effective preventive treatment for chronic migraine, offering potential benefits for patients and healthcare providers in China.